Literature DB >> 1711943

Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease.

E Hachulla1, R Saile, H J Parra, P Y Hatron, D Gosset, J C Fruchart, B Devulder.   

Abstract

A prospective clinical study of 23 patients with giant-cell arteritis (GCA) and/or polymyalgia rheumatica (PMR) was undertaken in order to assess the behaviour of the non-specific markers of the disease activity, the erythrocyte sedimentation rate (ESR) and other acute phase markers, particularly the C-reactive protein (CPR) and serum amyloid A apolipoprotein (apo SAA) levels during induction of disease remission by prednisone therapy, and possible further recurrence of GCA and/or PMR. The apo SAA measurement is more sensitive than the CRP measurement in determining disease activity (97% and 61%, respectively). The specificity of apo SAA is greater than ESR in the determination of inactive disease (86% and 77%, respectively). In some cases with clinically active disease the ESR and CRP were normal, whereas the apo SAA was always elevated. We conclude that the apo SAA measurement in combination with clinical data and other laboratory parameters may be useful in the management of GCA and/or PMR.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711943

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

Review 1.  [Clinical and serological findings of giant-cell arteritis].

Authors:  P Vaith; K Warnatz
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

Review 2.  Mechanism and biomarkers in aortitis--a review.

Authors:  Benjamin Benhuri; Ammar ELJack; Bashar Kahaleh; Ritu Chakravarti
Journal:  J Mol Med (Berl)       Date:  2019-10-30       Impact factor: 4.599

Review 3.  Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

Authors:  Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

4.  Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis.

Authors:  Luca Cantarini; Teresa Giani; Antonella Fioravanti; Francesca Iacoponi; Gabriele Simonini; Ilaria Pagnini; Adriano Spreafico; Federico Chellini; Mauro Galeazzi; Rolando Cimaz
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

5.  Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis.

Authors:  Sang Youn Jung; Min-Chan Park; Yong-Beom Park; Soo-Kon Lee
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.